Beijing Phaebus NewSky Pharmaceutical Technology Co., Ltd. (shortened to Phaebus NewSky) recently announced the completion of a Pre‑A financing round of nearly 100 million RMB. This round was led by YuanSheng Venture Capital, with Shunwei Capital, Taiyu Ankang, and Beijing Xinghang participating as follow‑on investors, and Chana Capital acting as the exclusive financial advisor. The funds raised will be primarily used for regulatory filings of the company’s proprietary products and for R&D investment in subsequent new products.

Phaebus NewSky is a medical device R&D and manufacturing company focused on innovative drug development in the field of nuclear medicine, specializing in providing end‑to‑end solutions for transforming scientists’ independent innovations into commercial outcomes.

Beijing Caihe Law Firm conducted Freedom‑to‑Operate (FTO) due diligence for patent infringement risks in this financing round.